We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

139 hedge funds and large institutions have $1.34B invested in Amicus Therapeutics in 2015 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 64 increasing their positions, 35 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 35

6% more call options, than puts

Call options by funds: $11.3M | Put options by funds: $10.6M

5% less funds holding

Funds holding: 147139 (-8)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

18% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 34

24% less capital invested

Capital invested by funds: $1.76B → $1.34B (-$414M)

Holders
139
Holders Change
-8
Holders Change %
-5.44%
% of All Funds
3.65%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.16%
New
28
Increased
64
Reduced
35
Closed
34
Calls
$11.3M
Puts
$10.6M
Net Calls
+$675K
Net Calls Change
+$842K
Name Holding Trade Value Shares
Change
Change in
Stake
PAMU
26
Pictet Asset Management (UK)
United Kingdom
$9.35M +$1.33M +148,112 +18%
UBS AM
27
UBS AM
Illinois
$9.28M +$51.4K +5,700 +0.6%
JP Morgan Chase
28
JP Morgan Chase
New York
$8.87M +$4.34M +481,760 +111%
VOYA Investment Management
29
VOYA Investment Management
Georgia
$8.48M +$6.07M +673,950 +337%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$7.84M +$528K +58,610 +8%
Invesco
31
Invesco
Georgia
$7.5M +$349K +38,725 +5%
Deutsche Bank
32
Deutsche Bank
Germany
$7.46M +$2.03M +224,754 +41%
CS
33
Candriam SCA
Luxembourg
$7.41M -$1.62M -180,000 -19%
PI
34
Putnam Investments
Massachusetts
$7.05M
Massachusetts Financial Services
35
Massachusetts Financial Services
Massachusetts
$6.85M -$44.2K -4,908 -0.7%
Norges Bank
36
Norges Bank
Norway
$6.6M -$890K -98,717 -13%
Prudential Financial
37
Prudential Financial
New Jersey
$5.96M +$1.53M +170,200 +38%
OAM
38
Oxford Asset Management
United Kingdom
$5.96M +$5.54M +614,976 New
RSCM
39
Rock Springs Capital Management
Maryland
$5.5M +$1M +111,500 +25%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$5.33M -$276K -30,617 -5%
Asset Management One
41
Asset Management One
Japan
$5.03M +$1.26M +140,311 +37%
ARTA
42
A.R.T. Advisors
New York
$4.96M +$4.61M +511,384 New
Group One Trading
43
Group One Trading
Illinois
$3.93M +$2.39M +264,878 +189%
BIM
44
BlackRock Investment Management
Delaware
$3.79M +$17K +1,887 +0.5%
Charles Schwab
45
Charles Schwab
California
$3.57M +$177K +19,590 +6%
TCIM
46
TIAA CREF Investment Management
New York
$3.47M -$84.4K -9,364 -3%
California Public Employees Retirement System
47
California Public Employees Retirement System
California
$3.16M +$105K +11,600 +4%
GC
48
Guggenheim Capital
Illinois
$2.82M +$1.25M +138,233 +91%
CCI
49
Columbus Circle Investors
$2.21M +$1.13M +125,574 +123%
GKIM
50
GW&K Investment Management
Massachusetts
$2.17M +$842K +93,385 +72%

FOLD Hedge Fund Activity: Q4 2015 in Review

139 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2015, worth a combined $1.34B — down 24% from $1.76B a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of FOLD and 28 opened new positions — a net loss of 6 holders — while 35 trimmed existing stakes and 64 added.

The largest buyer was Fidelity Investments, adding an estimated $35.5M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $38.5M sold.

  • 139 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2015, down from 147 in Q3 2015.
  • Funds reported $1.34B of Amicus Therapeutics stock for Q4 2015, down 24% quarter-over-quarter.
  • 28 funds opened new Amicus Therapeutics positions in Q4 2015 and 34 closed out, a net change of -6 holders.
  • The largest Amicus Therapeutics buyer in Q4 2015 was Fidelity Investments, an estimated $35.5M added.
  • The largest Amicus Therapeutics seller in Q4 2015 was Lord, Abbett & Co, an estimated $38.5M sold.

Based on aggregated 13F filings for Q4 2015.